Facebook
Twitter
LinkedIn
ForwardSponsored Webinar: Implementing Procalcitonin in Your Hospital to Maximize Antibiotic Stewardship
Webinar Description:
Sponsored by Roche
Procalcitonin (PCT) has been well established in clinical practice for the use among patients with lower respiratory tract infections (LRTIs) and bacterial infections, but there is a broader application with patients on antibiotics. Joseph Kuti, PharmD will share how the use of PCT has evolved within the Hartford HealthCare system to include the biomarker in the antibiotic management of COVID-19 patients. He will also discuss the operational pull through of the biomarker across multidisciplinary teams that include the pharmacy.
This course was originally recorded on 3/4/21 as part of the Sepsis Alliance Clinical Community Sponsor Innovation Day.
Target Audience
Nurses, physician assistants, physicians, emergency responders, physical therapists, patient care assistants, and other healthcare staff
Learning Objectives
At the end of the presentation, the attendee should be able to:
- Articulate the evolution of the use case for PCT to include patients with viral infections on antibiotics.
- Understand how a multidisciplinary team can adopt biomarkers to improve antibiotic stewardship.
Sepsis Alliance gratefully acknowledges the support provided for this sponsor innovation webinar by Roche.
Joseph Kuti, PharmD
Associate Director of Clinical and Economic Studies at the Center for Anti-Infective Research and Development at Hartford Hospital in Hartford, Connecticut
Dr. Joseph Kuti received his Bachelor of Science and Doctor of Pharmacy degrees from Rutgers University, College of Pharmacy in Piscataway, New Jersey. He then completed a post-doctorate fellowship in Antibiotic Management and Pharmacoeconomics at Hartford Hospital. Dr. Kuti is a member of the American Society for Microbiology, Infectious Disease Society of America, and past-President and honorary Fellow of the Society of Infectious Diseases Pharmacists. He is also an advisor to the CLSI Antibiotic Susceptibility Testing Subcommittee. Dr. Kuti’s primary area of research includes the pharmacokinetics, pharmacodynamics, and outcomes of antimicrobial management of severe infections. His research has been published in over 200 peer-reviewed papers.
No continuing education credits are offered for this sponsored webinar.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.